Olaratumab and doxorubicin versus doxorubicin alone in soft tissue sarcoma

BACKGROUND: Median overall survival for patients with metastatic soft tissue sarcoma is 12 to 16 months. Olaratumab is a human anti–platelet-derived growth factor receptor α monoclonal antibody which has antitumour activity in human sarcoma xenografts. METHODS: We conducted an open-label phase 1b, r...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Lancet
Glavni autori: Tap, William D., Jones, Robin L., Van Tine, Brian A., Chmielowski, Bartosz, Elias, Anthony D., Adkins, Douglas, Agulnik, Mark, Cooney, Matthew M., Livingston, Michael B., Pennock, Gregory, Hameed, Meera R., Shah, Gaurav D., Qin, Amy, Shahir, Ashwin, Cronier, Damien M., Ilaria, Robert, Conti, Ilaria, Cosaert, Jan, Schwartz, Gary K.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5647653/
https://ncbi.nlm.nih.gov/pubmed/27291997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(16)30587-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items